Frequency Therapeutics Closes $62MM Series C Financing


Congratulations to Frequency Therapeutics!

They have announced the close of their $62mm Series C financing to expand research of their innovative drug candidate for hearing restoration and its potential for other degenerative diseases using their first-in-class Progenitor Cell Activation platform.

https://www.linkedin.com/feed/update/urn:li:activity:6559391537099264001

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • LinkedIn Social Icon

© 2019 by CreaGen Inc. 

299 Washington St

Woburn, MA 01801 

Tel: 781.938.1122

Fax: 781.938.1123

 

info@creagenbio.com

  • Grey LinkedIn Icon
  • Grey Twitter Icon
  • Grey YouTube Icon
  • Grey Facebook Icon

Business Accelerator | CreaGen C2I | Life Science | Lease Lab Space | Biotech